Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for hospitalized COVID-19 pneumonia: pilot study
2020-001475-33Phase 2Terminated
- Sponsor
- University of Perugia
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of colchicine in coronavirus pneumonia and coronavirus disease 2019 (COVID-19), sponsored by University of Perugia. Primary endpoint: One-month clinical worsening rate. Started Jun 2020; status: terminated.
02
Drugs
colchicine
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001475-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001475-33.